• Opinion: STAT+ Conversations: An inside look at STAT's First Opinion

    11 days ago - By STAT

    Each week, STAT Plus subscribers get exclusive access to live discussions with STAT reporters and leaders in health and medicine.
    This week, STAT's co-founder and executive editor, Rick Berke, will be joined by the editor of STAT's First Opinion section , Patrick Skerrett. They'll give you an inside look at how the column gets made - and tell you what it takes to be a standout contributor, as the column recently celebrated 2,000 published essays.
    Read more ...

     

  • STAT Plus: Compass Pathways set to become the first psychedelic biotech IPO

    11 days ago - By STAT

    Compass Pathways isn't the first company to fashion FDA-regulated therapies out of psilocybin, but it intends to be the first one to go public.
    This week, the British company is seeking to raise about $100 million at a $570 million valuation. Compass, which counts Thiel Capital among its private investors, intends to sell 6.7 million shares for between $14 and $16 each. The funds will support an ongoing Phase 2b trial intended to prove that psilocybin-based therapy can help patients with treatment-resistant depression. Continue to STAT Plus to read the full story...
    Read more ...